Eli Lilly and Company, UnitedHealth Group, and 180 Life Sciences are the three Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks are shares of publicly traded companies operating within the healthcare sector, including pharmaceutical manufacturers, biotechnology firms, medical-device producers and healthcare service providers. Investors trade these stocks to gain exposure to the research, development and commercialization of medical treatments and technologies. Their performance often hinges on clinical trial outcomes, regulatory approvals and shifts in healthcare policy. These companies had the highest dollar trading volume of any Medical stocks within the last several days.
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Eli Lilly and Company stock traded up $5.20 during mid-day trading on Tuesday, hitting $640.42. The company's stock had a trading volume of 3,902,631 shares, compared to its average volume of 4,073,039. The stock has a market cap of $606.13 billion, a price-to-earnings ratio of 41.85, a price-to-earnings-growth ratio of 0.87 and a beta of 0.44. The business has a 50 day moving average price of $771.87 and a 200-day moving average price of $798.30. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $972.53.
Read Our Latest Research Report on LLY
UnitedHealth Group (UNH)
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage.
NYSE UNH traded up $7.57 on Tuesday, hitting $259.94. The company's stock had a trading volume of 7,812,556 shares, compared to its average volume of 12,070,603. UnitedHealth Group has a 52-week low of $234.60 and a 52-week high of $630.73. The company has a current ratio of 0.85, a quick ratio of 0.85 and a debt-to-equity ratio of 0.73. The company's 50-day simple moving average is $290.74 and its 200 day simple moving average is $403.22. The firm has a market cap of $235.80 billion, a P/E ratio of 11.26, a PEG ratio of 1.62 and a beta of 0.43.
Read Our Latest Research Report on UNH
180 Life Sciences (ATNF)
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.
ATNF stock traded up $5.10 during trading on Tuesday, reaching $8.44. The company had a trading volume of 153,316,593 shares, compared to its average volume of 2,010,874. 180 Life Sciences has a 52 week low of $0.66 and a 52 week high of $17.75. The company has a market cap of $50.95 million, a P/E ratio of -0.56 and a beta of 0.38. The business has a 50 day moving average of $1.64 and a 200 day moving average of $1.29.
Read Our Latest Research Report on ATNF
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access